“We estimate that the use of drug delivery systems will experience a significant growth - from 20% today to 80% in 2010. This drug delivery system will make a difference to severely ill patients on a global level”

Palle Schelde, CEO

Future potential

LiPlasome has successfully concluded part of our preclinical development programme and demonstrated proof of principle in animal studies of the novel tumor activated prodrug and drug delivery platform and are about to enter phase one with our chemotherapeutic platform.

We are continuously preparing new patent applications protecting novel and broad aspects of our targeted drug delivery technology to diseased regions characterized by elevated levels of phospholipase A₂